<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="378" end="385" sStart="355" offset="23" sid="r10.wait.v.0830" wn="1" wnkey="wait%2:42:00::" annotator="anfahmy" text="As an analogy, imagine waiting at a bus stop C for a bus traveling north to destination D. Suppose you walk south and board the same bus at stop B prior to its arrival at C. Although the bus ride from B to D is longer than from C to D (by the lead time from B to C), the arrival time at D is unchanged." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="16767" end="16771" sStart="null" offset="181" sid="r11.true.j.0337" wn="1" wnkey="true%3:00:00::" annotator="vebatchelder" text="If one used the estimated difference in cancer mortality at the end of a 3-year follow-up period, this estimate would likely be biased relative to the true difference at 5 years." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="27701" end="27707" sStart="null" offset="81" sid="r11.strong.j.0666" wn="1 6 5" wnkey="null" annotator="adelpriore" text="Thus randomized screening trials should only be undertaken when there is strong preliminary evidence for a potential benefit of screening that could outweigh attendant harms." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="10983" end="10992" sStart="null" offset="8" sid="r11.recommend.v.0430" wn="1" wnkey="recommend%2:32:01::" annotator="vebatchelder" text="We also recommend that all deaths and their causes be reported." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="10650" end="10659" sStart="null" offset="33" sid="r11.recommend.v.0049" wn="1" wnkey="recommend%2:32:01::" annotator="anfahmy" text="For practical considerations, we recommend using cancer death as an endpoint with careful review of the death records to minimize sticky-diagnosis and slippery linkage bias." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="30512" end="30521" sStart="null" offset="43" sid="r11.recommend.v.0022" wn="1" wnkey="recommend%2:32:01::" annotator="anfahmy" text="Because the assumptions are reasonable, we recommend these guidelines as one of the primary analyses." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="10829" end="10838" sStart="null" offset="8" sid="r11.recommend.v.0429" wn="1" wnkey="recommend%2:32:01::" annotator="adelpriore" text="We also recommend that &quot;cancer&quot; deaths include any non-cancer deaths attributable to screening or treatment for the cancer." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="10650" end="10659" sStart="null" offset="33" sid="r11.recommend.v.0049" wn="1" wnkey="recommend%2:32:01::" annotator="adelpriore" text="For practical considerations, we recommend using cancer death as an endpoint with careful review of the death records to minimize sticky-diagnosis and slippery linkage bias." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="30512" end="30521" sStart="null" offset="43" sid="r11.recommend.v.0022" wn="1" wnkey="recommend%2:32:01::" annotator="adelpriore" text="Because the assumptions are reasonable, we recommend these guidelines as one of the primary analyses." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2288-2-11.anc" start="29033" end="29037" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" annotator="cgozo" text="Case-control studies are applicable with special considerations for cancer screening [ 22 ] . Periodic Screening Evaluation (PSE) is a method for using data from subjects of various age who receive at least two regularly scheduled screenings to estimate the reduction in cancer mortality from periodic screening over a range of ages [ 23 24 ] . The main assumptions of PSE are (1) once a cancer is detectable on screening it would be detectable on later screenings (2) given age, year of birth adds no information for predicting the detection &lt;b&gt;rate&lt;/b&gt; on the first screen, (3) no selection bias in using refusers to estimate survival from detection in the absence of screening." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2288-2-11.anc" start="29033" end="29037" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" annotator="brubin" text="Case-control studies are applicable with special considerations for cancer screening [ 22 ] . Periodic Screening Evaluation (PSE) is a method for using data from subjects of various age who receive at least two regularly scheduled screenings to estimate the reduction in cancer mortality from periodic screening over a range of ages [ 23 24 ] . The main assumptions of PSE are (1) once a cancer is detectable on screening it would be detectable on later screenings (2) given age, year of birth adds no information for predicting the detection &lt;b&gt;rate&lt;/b&gt; on the first screen, (3) no selection bias in using refusers to estimate survival from detection in the absence of screening." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2288-2-11.anc" start="19335" end="19340" sStart="null" offset="0" sid="null" wn="6" wnkey="power%1:10:00::" annotator="veweser" text="A third approach is to select follow-up times based on maximum &lt;b&gt;power&lt;/b&gt; given parameter estimates from previous trials and the effect size that one would like to detect [ 16 ] ." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2288-2-11.anc" start="19335" end="19340" sStart="null" offset="0" sid="null" wn="3" wnkey="power%1:09:01::" annotator="tofox" text="A third approach is to select follow-up times based on maximum &lt;b&gt;power&lt;/b&gt; given parameter estimates from previous trials and the effect size that one would like to detect [ 16 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="11212" end="11222" sStart="null" offset="163" sid="r10.particular.j.0590" wn="2" wnkey="particular%5:00:02:specific:00" annotator="anfahmy" text="If, after adjusting for multiple comparisons, there is a statistically significant difference between groups in the estimated probability of a particular non-cancer cause of death, the investigators should reexamine the death records to check for potential biases." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="20177" end="20183" sStart="null" offset="31" sid="r8.number.n.0197" wn="1" wnkey="number%1:07:00::" annotator="veweser" text="Letting n denote the number of subjects in each group, we define" />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2288-2-11.anc" start="18904" end="18908" sStart="null" offset="0" sid="null" wn="1" wnkey="long%3:00:02::" annotator="brubin" text="A related problem is that t catch-up might not occur for a very &lt;b&gt;long&lt;/b&gt; &lt;b&gt;time&lt;/b&gt;, making its calculation impractical." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="753" end="757" sStart="null" offset="45" sid="r8.life.n.0364" wn="3" wnkey="life%1:26:02::" annotator="cgozo" text="You have simply spent more of your life on the bus." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="25966" end="25970" sStart="null" offset="98" sid="r10.high.j.0685" wn="1" wnkey="high%3:00:02::" annotator="veweser" text="On a fundamental level, cancer-screening trials differ from therapy trials because of the high amount of &quot;noise&quot; relative to the &quot;signal&quot; of screening effect." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="14379" end="14383" sStart="null" offset="111" sid="r9.full.j.0160" wn="2" wnkey="full%5:00:01:whole:00" annotator="brubin" text="As derived by Zelen [ 11 ] , the adjusted sample size is the sample size if there were full attendance and no contamination divided by (f 1 - f 0 ) 2." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="13637" end="13643" sStart="null" offset="45" sid="r9.fold.v.0484" wn="2" wnkey="fold%2:30:00::" annotator="brubin" text="The effect of later switching is folded into the interpretation." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="12965" end="12969" sStart="null" offset="130" sid="r7.1.face.n.0335" wn="6" wnkey="face%1:15:00::" annotator="brubin" text="Unfortunately neither of the assumptions is verifiable, but they are reasonable, and therefore have &quot;face&quot; validity." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="29319" end="29328" sStart="null" offset="139" sid="r8.1.different.j.0689" wn="1" wnkey="different%3:00:00::" annotator="veweser" text="The paired availability design (PAD) is a method for combining data from various before-and-after studies that adjusts for different fraction receiving the intervention in a manner similar to that for nonattendance and contamination [ 25 ] . For applications to screening, PAD requires a well-defined geographic region in which screening has been introduced, with little in- or -out- migration and no other changes over time that would affect the endpoint of cancer mortality." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="7708" end="7715" sStart="null" offset="199" sid="r10.control.n.0719" wn="4" wnkey="control%1:09:02::" annotator="cgozo" text="Under the null hypothesis, the probability of cancer death in each group is p . Under the alternative hypothesis the probability of cancer death is p in the control group and p-d in the study group, where d is the probability of cancer death in the control group minus the probability of cancer death in the screened group." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="15414" end="15421" sStart="null" offset="83" sid="r10.control.n.0519" wn="4" wnkey="control%1:09:02::" annotator="cgozo" text="We can identify subjects with B = 1 in the screened group but not in the control group." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="8988" end="8995" sStart="null" offset="132" sid="r10.control.n.0904" wn="4" wnkey="control%1:09:02::" annotator="brubin" text="Under the alternative hypothesis the probability of death from all causes is p + k in the control group and ( p + k )-( d - e ) in the screened group, where e is the additional probability of non-cancer deaths due to screening." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="26211" end="26217" sStart="null" offset="178" sid="r10.common.j.0799" wn="4" wnkey="common%5:00:00:familiar:02" annotator="cgozo" text="This &quot;noise&quot; arises because cancer deaths are rare relative to all deaths, non-attendance and contamination immediately after randomization are common, and discontinuation of screening leads to a dilution of cancer deaths due to cases arising after screening has stopped." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2288-2-11.anc" start="16892" end="16898" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="tofox" text="Thus, the longer the longer the follow-up period (up to some point) the less &lt;b&gt;chance&lt;/b&gt; for bias due to excluding long-term effects of screening." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2288-2-11.anc" start="16892" end="16898" sStart="null" offset="0" sid="null" wn="4" wnkey="chance%1:07:00::" annotator="comcgeetubb" text="Thus, the longer the longer the follow-up period (up to some point) the less &lt;b&gt;chance&lt;/b&gt; for bias due to excluding long-term effects of screening." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2288-2-11.anc" start="16892" end="16898" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="chisom" text="Thus, the longer the longer the follow-up period (up to some point) the less &lt;b&gt;chance&lt;/b&gt; for bias due to excluding long-term effects of screening." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="29158" end="29165" sStart="null" offset="748" sid="r11.absence.n.0055" wn="1" wnkey="absence%1:26:00::" annotator="anfahmy" text="Case-control studies are applicable with special considerations for cancer screening [ 22 ] . Periodic Screening Evaluation (PSE) is a method for using data from subjects of various age who receive at least two regularly scheduled screenings to estimate the reduction in cancer mortality from periodic screening over a range of ages [ 23 24 ] . The main assumptions of PSE are (1) once a cancer is detectable on screening it would be detectable on later screenings (2) given age, year of birth adds no information for predicting the detection rate on the first screen, (3) no selection bias in using refusers to estimate survival from detection in the absence of screening." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-2-11.anc" start="29158" end="29165" sStart="null" offset="748" sid="r11.absence.n.0055" wn="1" wnkey="absence%1:26:00::" annotator="adelpriore" text="Case-control studies are applicable with special considerations for cancer screening [ 22 ] . Periodic Screening Evaluation (PSE) is a method for using data from subjects of various age who receive at least two regularly scheduled screenings to estimate the reduction in cancer mortality from periodic screening over a range of ages [ 23 24 ] . The main assumptions of PSE are (1) once a cancer is detectable on screening it would be detectable on later screenings (2) given age, year of birth adds no information for predicting the detection rate on the first screen, (3) no selection bias in using refusers to estimate survival from detection in the absence of screening." />
  </sentences>
</list>